Where endometrial cancer treatment is heading
Endometrial cancer · Updated Nov 13, 2026
About 67,000 people in the US are diagnosed with endometrial (uterine) cancer each year, and it is rising faster than most cancers. Surgery cures most early cases. For advanced or recurrent disease, chemotherapy plus immunotherapy is now standard, and testing a tumor's molecular profile (mismatch-repair status and more) increasingly decides treatment at every stage.
- 556studies open or running
- 49phase 3 trials
- 2,367papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
A cure may be possible for someHappened 54% estimated cure rate
In dMMR tumors, a model estimates 54% of people on dostarlimab plus chemotherapy may be cured.
54%: estimated cure rate with dostarlimab.
Immunotherapy helps nearly everyoneHappened
Pembrolizumab plus chemotherapy improved outcomes regardless of mismatch-repair status.
A combination that worked later did not work firstHappened
Lenvatinib plus pembrolizumab failed to beat chemotherapy, and caused more side effects, as a first treatment.
A tumor's molecular profile can reduce radiationHappened
Matching treatment to molecular risk, not just stage, let many women safely have less radiation.
-
6 months
by May 2027
An antibody for a newer targetPossible
AstraZeneca's 800-person phase 3 of puxitatug samrotecan, aimed at the B7-H4 protein, is recruiting; due October 2027.
-
12 months
by Nov 2027
More molecular-profile trials maturePossible
Results building on PORTEC-4a will refine which women can safely skip radiation or chemotherapy.
-
3 years
by late 2029
A HER2-targeted antibody-drug conjugatePossible
DESTINY-Endometrial01 (600 people) tests trastuzumab deruxtecan for HER2-expressing tumors; due January 2029.
A TROP2-targeted antibody with immunotherapyLong shot
Merck's 1,123-person TroFuse-033 pairs sacituzumab tirumotecan with pembrolizumab; due 2032.
-
5 years
by late 2031
Maintenance therapy refined furtherLong shot
DUO-E, testing olaparib added to durvalumab maintenance, continues to mature; may further split treatment by molecular subtype.
The research paths
Immunotherapy and biomarker-guided care
54% estimated cure rateDetailsHide
Mismatch-repair and other molecular tests now shape treatment from early surgery through advanced disease.
WatchLonger RUBY follow-up; PORTEC-4a adoption.
Antibody-drug conjugates
Details and 3 trialsHide
Targeted chemotherapy carriers aimed at B7-H4, HER2 and TROP2.
WatchDESTINY-Endometrial01; TroFuse trials.
- Puxitatug samrotecan, B7-H4 antibody-drug conjugate (DEL-ETE-01)AstraZeneca · 800 people · enrolling Oct 2027
- Trastuzumab deruxtecan plus rilvegostomig (DESTINY-Endometrial01)AstraZeneca · 600 people · enrolling Jan 2029
- Sacituzumab tirumotecan with pembrolizumab (TroFuse-033)Merck · 1,123 people · enrolling May 2032
Targeted pills and maintenance
Details and 1 trialsHide
Combinations that work later in treatment do not always work as a first treatment.
WatchDUO-E maturing data.
Borrowed from other cancers
From Breast and stomach cancer
Trastuzumab deruxtecan
Phase 3
A HER2 antibody-drug conjugate now tested in HER2-expressing endometrial cancer.
From Lung and breast cancer research
Sacituzumab tirumotecan
Phase 3
A TROP2-targeted antibody-drug conjugate.
From Ovarian and breast cancer (BRCA)
Olaparib
Approved for molecular subgroups
A PARP inhibitor tested as maintenance alongside immunotherapy.
Open to join now
-
B7-H4-selected, advanced
Puxitatug samrotecan (B7-H4 ADC)
Locations and eligibility → -
HER2-expressing, advanced
Trastuzumab deruxtecan combination
Locations and eligibility → -
Advanced, first treatment
Sacituzumab tirumotecan with pembrolizumab
Locations and eligibility →
See every recruiting Endometrial cancer trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
RUBY 4-year data: 54% estimated cure rate
dMMR tumors, Gynecologic Oncology.
Molecular profiling guides radiation decisions
PORTEC-4a, Lancet Oncology.
Lenvatinib plus pembrolizumab fails as first treatment
LEAP-001, J Clin Oncol.
Standard treatment today
- Early, low riskSurgery (hysterectomy) alone.
- Early, higher riskSurgery, then radiation or chemoradiation, now often guided by molecular profile.
- Advanced or recurrent, dMMRChemotherapy plus dostarlimab or pembrolizumab.
- Advanced or recurrent, pMMRChemotherapy plus pembrolizumab; lenvatinib plus pembrolizumab after chemo fails.
How to read this page, and sourcesHow to read this page, and sources
- Mismatch-repair status (dMMR vs pMMR) changes which results apply; the two groups respond differently to immunotherapy.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Endometrial cancer trials recruiting now →